User profiles for Thomas J. Galloway
 | Thomas J GallowayAssociate Professor of Radiation Oncology, Fox Chase Cancer Center Verified email at fccc.edu Cited by 5439 |
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non …
…, SA Seaward, S Spencer, TJ Galloway, J Phan… - The Lancet, 2019 - thelancet.com
Background Patients with human papillomavirus (HPV)-positive oropharyngeal squamous
cell carcinoma have high survival when treated with radiotherapy plus cisplatin. Whether …
cell carcinoma have high survival when treated with radiotherapy plus cisplatin. Whether …
[HTML][HTML] Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the …
…, C Silverman, A Raben, TJ Galloway… - Journal of Clinical …, 2014 - ncbi.nlm.nih.gov
… J Clin Oncol … J Clin Oncol … E 1308: A phase II trial of induction chemotherapy (IC)
followed by cetuximab with low dose versus standard dose IMRT in patients with human …
followed by cetuximab with low dose versus standard dose IMRT in patients with human …
[HTML][HTML] Survival impact of increasing time to treatment initiation for patients with head and neck cancer in the United States
CT Murphy, TJ Galloway, EA Handorf… - Journal of Clinical …, 2016 - ncbi.nlm.nih.gov
Purpose To estimate the overall survival (OS) impact from increasing time to treatment
initiation (TTI) for patients with head and neck squamous cell carcinoma (HNSCC). Methods …
initiation (TTI) for patients with head and neck squamous cell carcinoma (HNSCC). Methods …
Increasing time to treatment initiation for head and neck cancer: an analysis of the National Cancer Database
CT Murphy, TJ Galloway, EA Handorf, L Wang… - Cancer, 2015 - Wiley Online Library
BACKGROUND The objective of this study was to identify trends and predictors of the time
to treatment initiation (TTI) for patients with head and neck squamous cell carcinoma (HNSCC)…
to treatment initiation (TTI) for patients with head and neck squamous cell carcinoma (HNSCC)…
p16 status, pathologic and clinical characteristics, biomolecular signature, and long‐term outcomes in head and neck squamous cell carcinomas of unknown primary
LM Keller, TJ Galloway, T Holdbrook, K Ruth… - Head & …, 2014 - Wiley Online Library
Background The purpose of this study was to report associations between p16 status,
clinicopathologic characteristics, and outcomes for head and neck squamous cell carcinoma of …
clinicopathologic characteristics, and outcomes for head and neck squamous cell carcinoma of …
[PDF][PDF] Management of squamous cancer metastatic to cervical nodes with an unknown primary site
TJ Galloway, JA Ridge - Journal of Clinical Oncology, 2015 - Citeseer
… Conception and design: All authors Collection and assembly of data: Thomas J. Galloway
Data analysis and interpretation: All authors Manuscript writing: All authors Final approval of …
Data analysis and interpretation: All authors Manuscript writing: All authors Final approval of …
Psychological functioning of caregivers for head and neck cancer patients
Patients with head and neck squamous cell carcinoma (HNSCC) often require assistance
from family caregivers during the treatment and post-treatment period. This review article …
from family caregivers during the treatment and post-treatment period. This review article …
The impact of radiation treatment time on survival in patients with head and neck cancer
…, CT Murphy, R Mehra, JA Ridge, TJ Galloway - International Journal of …, 2016 - Elsevier
Purpose To assess the impact of radiation treatment time (RTT) in head and neck cancers
on overall survival (OS) in the era of chemoradiation. Methods and Materials Patients with …
on overall survival (OS) in the era of chemoradiation. Methods and Materials Patients with …
A phase I study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with head and neck squamous cell …
TJ Galloway, LJ Wirth, AD Colevas, J Gilbert… - Clinical Cancer …, 2015 - AACR
Purpose: CUDC-101 is a small molecule that simultaneously inhibits the epidermal growth
factor receptor (EGFR), human growth factor receptor 2 (HER2), and histone deacetylase (…
factor receptor (EGFR), human growth factor receptor 2 (HER2), and histone deacetylase (…
Concurrent definitive immunoradiotherapy for patients with stage III–IV head and neck cancer and cisplatin contraindication
…, S Patel, TG Hackman, JM Blumberg, TJ Galloway… - Clinical Cancer …, 2020 - AACR
Purpose: Although cisplatin plus radiotherapy is a standard treatment of locally advanced
head and neck squamous cell carcinoma (LA-HNSCC), cisplatin contraindication is common. …
head and neck squamous cell carcinoma (LA-HNSCC), cisplatin contraindication is common. …
